TY - JOUR
T1 - Employment and social benefits up to 10 years after breast cancer diagnosis
T2 - A population-based study
AU - Palman, C.H.
AU - van Leeuwen, F.E.
AU - Aaronson, N.K.
AU - de Boer, A.G.E.M.
AU - van de Poll-Franse, L.
AU - Oldenburg, H.S.A.
AU - Schaapveld, M.
AU - Paalman, C. H.
PY - 2016
Y1 - 2016
N2 - Little is known about employment outcomes after breast cancer (BC) beyond the first years after treatment. Employment outcomes were compared with a general population comparison group (N=91 593) up to 10 years after BC for 26 120 patients, diagnosed before age 55 between 2000-2005, with income and social benefits data from Statistics Netherlands. Treatment effects were studied in 14 916 patients, with information on BC recurrences and new cancer events. BC survivors experienced higher risk of losing paid employment (Hazard Ratio (HR): 1.6, 95% Confidence Interval (95% CI) 1.4-1.8) or any work-related event up to 5-7 years (HR 1.5, 95% CI 1.3-1.6) and of receiving disability benefits up to 10 years after diagnosis (HR 2.0, 95% CI 1.6-2.5), with higher risks for younger patients. Axillary lymph node dissection increased risk of disability benefits (HR 1.5, 95% CI 1.4-1.7) or losing paid employment (HR 1.3, 95% CI 1.2-1.5) during the first 5 years of follow-up. Risk of disability benefits was increased among patients receiving mastectomy and radiotherapy (HR 1.2; 95% CI 1.1-1.3) and after chemotherapy (HR 1.7; 95% CI 1.5-1.9) during the first 5 years after diagnosis. BC treatment at least partly explains the increased risk of adverse employment outcomes up to 10 years after BC
AB - Little is known about employment outcomes after breast cancer (BC) beyond the first years after treatment. Employment outcomes were compared with a general population comparison group (N=91 593) up to 10 years after BC for 26 120 patients, diagnosed before age 55 between 2000-2005, with income and social benefits data from Statistics Netherlands. Treatment effects were studied in 14 916 patients, with information on BC recurrences and new cancer events. BC survivors experienced higher risk of losing paid employment (Hazard Ratio (HR): 1.6, 95% Confidence Interval (95% CI) 1.4-1.8) or any work-related event up to 5-7 years (HR 1.5, 95% CI 1.3-1.6) and of receiving disability benefits up to 10 years after diagnosis (HR 2.0, 95% CI 1.6-2.5), with higher risks for younger patients. Axillary lymph node dissection increased risk of disability benefits (HR 1.5, 95% CI 1.4-1.7) or losing paid employment (HR 1.3, 95% CI 1.2-1.5) during the first 5 years of follow-up. Risk of disability benefits was increased among patients receiving mastectomy and radiotherapy (HR 1.2; 95% CI 1.1-1.3) and after chemotherapy (HR 1.7; 95% CI 1.5-1.9) during the first 5 years after diagnosis. BC treatment at least partly explains the increased risk of adverse employment outcomes up to 10 years after BC
U2 - https://doi.org/10.1038/bjc.2015.431
DO - https://doi.org/10.1038/bjc.2015.431
M3 - Article
C2 - 26757424
SN - 0007-0920
VL - 114
SP - 81
EP - 87
JO - The British journal of cancer
JF - The British journal of cancer
IS - 1
ER -